Aankondiging • May 31

Aditxt, Inc. Receives Notice of Nasdaq Delisting Due to Multiple Listing Standard Deficiencies

On May 27, 2026, Aditxt, Inc. (the Company) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the stockholders’ equity of $(35,174,386) reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), the Company no longer satisfies the minimum stockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”). The Letter further notes that the Company does not presently satisfy either of the alternative continued listing standards under Nasdaq Listing Rule 5550(b) — a market value of listed securities of $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years (such non-compliance, the “Stockholders’ Equity Deficiency”). As previously disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 8, 2026, on May 6, 2026 the Company received a delisting determination from the Staff based on the Company’s failure to comply with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and the Company’s ineligibility for any compliance period under Nasdaq Listing Rule 5810(c)(3)(A)(iv) as a result of the Company’s reverse stock split history (the “Prior Determination”). The Company timely requested a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal the Prior Determination, which hearing is currently scheduled for June 11, 2026 (the “Hearing”). The Letter states that the Stockholders’ Equity Deficiency serves as an additional basis for delisting the Company’s securities from Nasdaq, and that the Panel will consider the Stockholders’ Equity Deficiency, together with the matters that were the subject of the Prior Determination, in rendering its determination regarding the Company’s continued listing on The Nasdaq Capital Market. The Company intends to present its views with respect to the Stockholders’ Equity Deficiency at the Hearing, together with its plan to evidence compliance with the minimum bid price requirement and the Stockholders’ Equity Requirement. In addition, the Company has determined that it is currently not in compliance with the requirement to maintain a minimum Market Value of Publicly Held Shares of $1,000,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(5) (such non-compliance, the “MVPHS Deficiency”). As of the date of this Current Report on Form 8-K, the Company has not received notification from the Staff with respect to the MVPHS Deficiency. If the Staff issues a separate deficiency determination relating to the MVPHS Deficiency, that matter may be considered by the Panel at or in connection with the Hearing in addition to the matters that were the subject of the Prior Determination and the Stockholders’ Equity Deficiency. There can be no assurance that the Company will be successful in its appeal before the Panel, that the Panel will grant the Company any additional period within which to regain compliance with the Stockholders’ Equity Requirement, the minimum bid price requirement, or any other applicable Nasdaq continued listing standard, or that, if any such period is granted, the Company will be able to evidence compliance with all applicable Nasdaq continued listing requirements within that period. The Panel has broad discretionary authority under the Nasdaq Listing Rules, including under Nasdaq Listing Rules 5101 and 5810(c)(1), to delist the Company’s securities notwithstanding the Company’s compliance efforts, including based on concerns regarding the Company’s prior reverse stock split history, financial condition, going concern, capital structure, capital-raising activities, or any other factor the Panel deems appropriate. If the Panel determines to delist the Company’s securities, or if the Company is otherwise unable to regain and maintain compliance with the applicable Nasdaq continued listing requirements, the Company’s common stock would be subject to delisting from The Nasdaq Capital Market, which would have a material adverse effect on the liquidity and market price of the Company’s common stock and on the Company’s ability to raise capital, which conditions would raise substantial doubt about our ability to continue as a going concern. If adequate working capital is not available, we may be forced to discontinue operations, which would cause investors to lose their entire investment.

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	4.6yrs
Gemiddelde ambtstermijn bestuur	geen gegevens

Naam	Positie	Tenure	Compensatie	Eigendom
Shahrokh Shabahang	Co-Founder	9.4yrs	US$325.00k	0% $ 0
Thomas Farley	Chief Financial Officer	4.8yrs	US$395.00k	0% $ 0
Corinne Pankovcin	Chief Mergers & Acquisitions Officer	4.2yrs	US$385.01k	geen gegevens
Jeffrey Busch	Chief Executive Officer	less than a year	geen gegevens	geen gegevens
Dolly Tyan	Senior Vice President of Clinical Development – Transplantation	5.4yrs	geen gegevens	geen gegevens
Ge Chen	Senior Vice President of Preclinical Research & Discovery	4.4yrs	geen gegevens	geen gegevens
Jennifer Lee	Director of Human Resources	no data	geen gegevens	geen gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/06/26 14:19
Aandelenkoers aan het einde van de dag	2026/06/25 00:00
Inkomsten	2026/03/31
Jaarlijkse inkomsten	2025/12/31

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

Aditxt Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Recent updates

Aditxt, Inc. Announces Delisting of Common Stock From The Nasdaq Stock Market LLC

Ignite Proteomics LLC entered into a definitive business combination agreement to acquire Copley Acquisition Corp (NYSE:COPL) from Copley Acquisition Sponsors, LLC and others for approximately $160 million in a reverse merger transaction.

Aditxt, Inc. Receives Notice of Nasdaq Delisting Due to Multiple Listing Standard Deficiencies

Aditxt, Inc.(NasdaqCM:ADTX) dropped from NASDAQ Composite Index

First quarter 2026 earnings released

CEO

Leiderschapsteam

Bedrijfsanalyse en status van financiële gegevens

Gegevensbronnen

Analysemodel en Snowflake

Industrie en sector

Bronnen van analisten